Related Experiment Video
Updated: May 24, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Emerging disease-modifying therapies in multiple sclerosis
1Department of Neurology, Weill Cornell Medical College, 1305 York Avenue, New York, NY, 10021, USA, jsp9007@med.cornell.edu.
Current Treatment Options in Neurology
|March 20, 2012
Summary
The expanding landscape of multiple sclerosis (MS) treatments offers more choices but necessitates careful patient-specific therapy selection. Future advancements in personalized medicine promise even better outcomes for MS patients.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) treatment has evolved significantly over the last 20 years.
- Numerous therapeutic options are now available, presenting challenges in selecting the optimal treatment for individual patients.
- Current first-line treatments include interferons and glatiramer acetate for newly diagnosed relapsing MS.
Purpose of the Study:
- To review the current therapeutic landscape for multiple sclerosis.
- To discuss the emerging treatment options and their potential roles as first-line agents.
- To explore the future of personalized medicine in MS treatment.
Main Methods:
- Review of current clinical practices and emerging therapies for multiple sclerosis.
- Discussion of the efficacy, safety, and tolerability profiles of various MS medications.
- Consideration of advancements in genetics and biomarkers for personalized treatment approaches.
Main Results:
- Several oral agents like fingolimod, BG-12, and teriflunomide show potential as first-line therapies.
- Natalizumab and fingolimod are primary options for patients with high disease activity or those refractory to initial treatments.
- Alemtuzumab is a highly efficacious option, though its use requires careful risk-benefit assessment.
Conclusions:
- The selection of MS therapy requires careful consideration of individual patient factors and disease characteristics.
- Personalized medicine, guided by genetics and biomarkers, is expected to optimize treatment selection.
- Future therapeutic advancements hold promise for significantly reducing the impact of MS on patients' lives.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.